18F-FDG-PET metabolic metrics and International Prognostic Score for risk assessment in HIV-infected patients with Hodgkin lymphoma

Lawal, Ismaheel; Ankrah, Alfred O.; Popoola, Gbenga; Nyakale, Nozipho; Boshomane, Tebatso; Reyneke, Florette; Lengana, Thabo; Vorster, Mariza; Sathekge, Mike

doi:10.1097/mnm.0000000000000905

Cited by 17 publications

(13 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be due to the fact that most of the HIV infected patients had good virologic suppression on anti-retroviral therapy. As we previously shown in patients with anal cancer and Hodgkin lymphoma, HIV-infection may be playing a limited role as a driver of aggressiveness in the ART era [28,29]. Regarding racial distribution of our study sample, we found the White population to be older compared with the Blacks with a difference tending towards a significant level.…”

Section: Discussionsupporting

confidence: 54%

18F-FDG PET/CT imaging of vulva cancer recurrence: A comparison of PET-derived metabolic parameters between women with and without HIV infection

et al. 2020

Self Cite

View full text Add to dashboard Cite

Objective To assess the patterns of recurrence of vulva cancer on 18F-FDG PET/CT and to compare the 18F-FDG PET metabolic metrics in patients with and without Human Immunodeficiency Virus (HIV). Methods Maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumour volume (MTV and total lesion glycolysis (TLG) were obtained on Flourine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) images of women referred with suspected or confirmed vulva cancer recurrence. We compared HIV-infected and HIV-uninfected patients regarding pattern disease recurrence, age at diagnosis, and the PET-derived metabolic indices. Results We analyzed 33 patients with a mean age 50.76 ± 15.78 including 21 HIV-infected women. The majority of patients (94 %) had squamous cell carcinoma and 84.85 % were Blacks. Of the HIV-infected individuals, the median CD4 count was 526.0 cells/mm3 (IQR: 379.0–729.0). HIV infected patients were younger than the HIV uninfected at the time of diagnosis: 40.50 ± 8.87 vs 66.54 ± 9.71 respectively, p < 0.001. We found a local (vulvar) recurrence rate of 75.8 %. Nodal pelvic recurrences were higher in the HIV-infected patients than in the HIV uninfected patients (70 % vs 30 %, p = 0.027). Three patients had distant metastasis and all three were HIV-infected. There was a higher whole-body MTV and TLG among HIV-infected women compared with HIV-uninfected women, 103.39 vs 17.58 and 852.64 vs 101.79, respectively (p < 0.05 for both). Conclusion HIV-infected women are diagnosed with vulva cancer at a younger age. HIV-infected patients had a higher rate of pelvic lymph node recurrence. There is a higher tumor burden at vulva cancer recurrence among women with HIV infection.

show abstract

Section: Discussionsupporting

confidence: 54%

18F-FDG PET/CT imaging of vulva cancer recurrence: A comparison of PET-derived metabolic parameters between women with and without HIV infection

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Interim PET-CT after two or three cycles can be used to decide if less chemotherapy can be given according to the to the metabolic response. A retrospective study by Lawal et al showed the usefulness of fluorine-18-fluorodeoxyglucose PET (FDG-PET) performed at diagnosis to stratify PLWH and cHL, without differences in metabolic parameters between HIV-positive and HIV-negative patients [77]. A study by Okosun et al demonstrated the utility of an interim FDC-PET after two or three cycles to predict outcomes in PLWH with advanced stage cHL treated with BVD [78].…”

Section: Treatment and Prognosismentioning

confidence: 99%

Hodgkin Lymphoma in People Living with HIV

Navarro

Moltó

Tapia

et al. 2021

Cancers

View full text Add to dashboard Cite

Despite widespread use of combined antiretroviral therapy (cART) and increased life expectancy in people living with HIV (PLWH), HIV-related lymphomas (HRL) remain a leading cause of cancer morbidity and mortality for PLWH, even in patients optimally treated with cART. While the incidence of aggressive forms of non-Hodgkin lymphoma decreased after the advent of cART, incidence of Hodgkin lymphoma (HL) has increased among PLWH in recent decades. The coinfection of Epstein–Barr virus plays a crucial role in the pathogenesis of HL in the HIV setting. Currently, PLWH with HRL, including HL, are treated similarly to HIV-negative patients and, importantly, the prognosis of HL in PLWH is approaching that of the general population. In this regard, effective cART during chemotherapy is strongly recommended since it has been shown to improve survival rates in all lymphoma subtypes, including HL. As a consequence, interdisciplinary collaboration between HIV specialists and hemato-oncologists for the management of potential drug–drug interactions and overlapping toxicities between antiretroviral and antineoplastic drugs is crucial for the optimal treatment of PLWH with HL. In this article the authors review and update the epidemiological, clinical and biological aspects of HL presenting in PLWH with special emphasis on advances in prognosis and the factors that have contributed to it.

show abstract

“…The clinical symptoms include abdominal discomfort, bloody stools, abdominal masses and systemic symptoms, such as fever, night sweats, fatigue and weight loss. 13 Clinically, NHL is broadly classified as indolent and aggressive based on its clinical presentation and biological features. To more accurately determine the malignancy and prognosis of lymphoma, biological parameters are used as predictors, such as the Ki-67 index, erythrocyte sedimentation rate, LDH and b2 microglobulin.…”

Section: Discussionmentioning

confidence: 99%

“… 12 The clinical symptoms include abdominal discomfort, bloody stools, abdominal masses and systemic symptoms, such as fever, night sweats, fatigue and weight loss. 13 …”

Section: Discussionmentioning

confidence: 99%

Correlation of 18F-FDG PET/CT SUVmax with clinical features, D-dimer and LDH in patients with primary intestinal lymphoma

et al. 2021

View full text Add to dashboard Cite

Objective To investigate the characteristics of fluorine-18-deoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) maximum standardized uptake value (SUVmax) in primary intestinal lymphoma (PIL) and its correlation with D-dimer and lactate dehydrogenase (LDH). Methods Fifty-two patients diagnosed with PIL from June 2016 to December 2019 were analyzed. All patients underwent 18F-FDG PET/CT. The relationships between SUVmax and different pathological subtypes, clinical stages and risk grades were analyzed. The correlations between SUVmax and Ki-67, LDH and D-dimer were determined. Additionally, PET/CT imaging results were collected from 35 patients with primary intestinal cancer (PIC) and compared with the imaging features of PIL. Results SUVmax was significantly different between PIL and PIC groups and various PIL pathological subgroups. Patients in the high-risk PIL group had markedly higher SUVmax values than the intermediate-risk and low-risk groups. A significant positive correlation was observed between SUVmax and Ki-67 in patients with PIL. SUVmax was significantly different between the elevated and normal D-dimer groups. D-dimer showed a positive correlation with SUVmax. Conclusion 18F-FDG PET/CT SUVmax reflects the aggressiveness of lymphoma to a certain degree, is correlated with Ki-67 and determines the risk grades of PIL. Moreover, it facilitates differential diagnosis, clinical staging and treatment based on D-dimer levels.

show abstract

18F-FDG-PET metabolic metrics and International Prognostic Score for risk assessment in HIV-infected patients with Hodgkin lymphoma

Abstract: There was no significant difference in F-FDG metabolic parameters, IPS, and other risk indicators between HIV-infected and HIV-uninfected patients with Hodgkin lymphoma.

Cited by 17 publications

References 25 publications

18F-FDG PET/CT imaging of vulva cancer recurrence: A comparison of PET-derived metabolic parameters between women with and without HIV infection

18F-FDG PET/CT imaging of vulva cancer recurrence: A comparison of PET-derived metabolic parameters between women with and without HIV infection

Hodgkin Lymphoma in People Living with HIV

Correlation of 18F-FDG PET/CT SUVmax with clinical features, D-dimer and LDH in patients with primary intestinal lymphoma

Contact Info

Product

Resources

About